Trial Profile
Effect of Ruxolitinib on Telomere Length and Bone marrow fibrosis in Patients with Myelofibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2017
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 21 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology